Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage

被引:124
|
作者
Moroni, Flavio [1 ]
机构
[1] Univ Florence, Dept Preclin & Clin Pharmacol, I-50135 Florence, Italy
关键词
D O I
10.1016/j.coph.2007.10.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(ADP-ribose) polymerases (PARPs) are enzymes that are able to catalyze the transfer of ADP-ribose units from NAD to substrate proteins and are particularly abundant in cell nuclei where they play key roles in the maintenance of genomic integrity, control of cell cycle and gene expression. Brain ischemia overactivates PARPs and PARP-deficient mice or animal treated with PARP inhibitors have a drastically reduced brain damage in various stroke models. PARP 'overactivation' occurs not only in neurons but also in astrocytes, microglial cells, endothelia, and infiltrating leukocytes. The ensuing cell death occurs through various molecular mechanisms: a) excessive ATP use for NAD synthesis and inhibition of mitochondrial function with subsequent energy failure (particularly important in neurons); b) apoptosis-inducing factor (AIF) translocation from the mitochondria to the nucleus (present in neurons, endothelial, and other cells); c) excessive expression of inflammatory mediators (well demonstrated in glial cells) or d) reduced expression of prosurvival factors. Thus PARPs seem to play key roles in postischemic brain damage and are now considered interesting targets for therapies aimed at reducing stroke pathology.
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [1] Poly(ADP-ribose) polymerase 1 (PARP-1) and post-ischemic brain damage
    Moroni, F.
    [J]. JOURNAL OF MOLECULAR NEUROSCIENCE, 2014, 53 : S92 - S92
  • [2] Poly ADP-Ribose polymerase (PARP-1) and DNA damage in pulmonary arterial hypertension
    Meloche, Jolyane
    Courboulin, Audrey
    Krietsch, Jana
    Margaillan, Guillaume
    Courchesne, Antony
    Coulombe, Yan
    Provencher, Steeve
    Poirier, Guy
    Masson, Jean-Yves
    Bonnet, Sebastien
    [J]. FASEB JOURNAL, 2013, 27
  • [3] POLY (ADP-RIBOSE) POLYMERASE-1 (PARP-1) INDUCES TROPHOBLAST SYNCYTIALIZATION
    Pater, Justin
    Shah, Girish
    MacPhee, Daniel
    [J]. PLACENTA, 2013, 34 (09) : A16 - A16
  • [4] The Pathogenic Role of Poly(ADP-ribose) Polymerase 1 (PARP-1) in Experimental Colitis
    Larmonier, Claire B.
    LaCasse, Collin J.
    Hill, Faihza M.
    Alizadeh, Darya
    Thurston, Robert D.
    Ghishan, Fayez K.
    Kiela, Pawel R.
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S885 - S886
  • [5] Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
    Sodhi, Rupinder K.
    Singh, Nirmal
    Jaggi, Amteshwar S.
    [J]. VASCULAR PHARMACOLOGY, 2010, 53 (3-4) : 77 - 87
  • [6] Poly (ADP-RIBOSE) Polymerase-1 (PARP-1) modulates astrocyte activation
    Phulwani, NK
    Kielian, T
    [J]. JOURNAL OF NEUROCHEMISTRY, 2006, 96 : 44 - 44
  • [7] Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy
    Cepeda, Victoria
    Fuertes, Miguel A.
    Castilla, Josefina
    Alonso, Carlos
    Quevedo, Celia
    Soto, Manual
    Perez, Jose M.
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (01) : 39 - 53
  • [8] Iniparib. Poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, Oncolytic
    Li, J.
    Glencer, A.
    Rugo, H. S.
    [J]. DRUGS OF THE FUTURE, 2012, 37 (11) : 777 - 786
  • [9] Docking and scoring inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1).
    Kumpf, RA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U409 - U409
  • [10] Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
    Tentori, Lucio
    Lacal, Pedro Miguel
    Muzi, Alessia
    Dorio, Annalisa Susanna
    Leonetti, Carlo
    Scarsella, Marco
    Ruffini, Federica
    Xu, Weizheng
    Min, Wokee
    Stoppacciaro, Antonella
    Colarossi, Cristina
    Wang, Zhao-Qi
    Zhang, Jie
    Graziani, Grazia
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (14) : 2124 - 2133